-
Rates of Recurrent VTE Compared for Apixaban, Rivaroxaban
Drugs
December 07, 2021
For patients with venous thromboembolism (VTE), new users of apixaban have lower rates of recurrent VTE and bleeding compared with new users of rivaroxaban, according to a study published online Dec. 7 in the Annals of Internal Medicine.
-
NICE backs restricted use of Ondexxya
pharmatimes
April 07, 2021
NHS cost regulators have backed funding for Alexion's Ondexxya (andexanet alfa) to reverse anticoagulation of the direct factor Xa (FXa) inhibitors apixaban or rivaroxaban in adults who experience a life-threatening or uncontrolled bleed in the ...
-
NATCO launches Rivaroxaban? anticoagulant medication in India
expresspharma
December 18, 2020
Natco Pharma announced the launch of Rivaroxaban molecule, under brand RPIGAT. Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots. Rivaroxaban is currently sold by Bayer under the brand name of Xarelto, in the Indian market.
-
NICE backs Portola's Ondexxya
pharmatimes
September 14, 2020
The National Institute for Health and Care Excellence (NICE) has published the outcome of an appraisal consultation document backing NHS funds for restricted use of Portola's Ondexxya (andexanet alfa) as an option for reversing anticoagulation ...
-
PPI Use for Up to Three Years Safe During Anticoagulant Tx
drugs
June 18, 2019
PPI Use for Up to Three Years Safe During Anticoagulant Tx.
-
Rivaroxaban reduced blood clots and related death in cancer patients
europeanpharmaceuticalreview
December 05, 2018
Through a clinical trial, Cleveland researchers have identified how rivaroxaban reduces blood clots in cancer patients and also decreases related deaths…
-
Low rates of stroke and major bleeding with rivaroxaban confirmed by global study
pharmaasia
October 16, 2017
John Battersby writes on the XANTUS real-world programme, the largest prospective observational study on a single NOAC for stroke prevention in AF.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
